Two new agents target KRAS G12C
Sign Up to like & getrecommendations! Published in 2019 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-019-0304-3
Abstract: Nature reviews | CliniCal OnCOlOgy Attempts to therapeutically target the products of the RAS oncogenes, frequently mutated in cancer, have had disappointing results thus far. The small molecules MRTX849 and AMG 510, from two independent… read more here.
Keywords: kras g12c; treatment; amg 510; oncology ... See more keywords
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.3003
Abstract: 3003 Background: The KRASG12C mutation is found in approximately 13% of lung adenocarcinomas and 1–3% of other solid tumors, but there is no approved therapy that targets this mutation. AMG 510 is a novel small… read more here.
Keywords: 510 novel; novel small; amg 510; krasg12c ... See more keywords
CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.3511
Abstract: 3511Background: Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G12C mutation occurs in approximately 13% of NSCLC and 1%–3% of CRC and other solid tumors. AMG 510 is a first-in-class small mol... read more here.
Keywords: codebreak 100; solid tumors; 100 phase; amg 510 ... See more keywords